Destiny Pharma – Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021

Future Pharma PLC (Goal:DEST) (Destiny Pharma PLC (Goal:DEST)) is a clinical stage, innovative biotechnology corporation focused on the progress of novel medicines that can avert lifestyle-threatening infections. The firm’s pipeline has novel microbiome-primarily based biotherapeutics and XF drug scientific assets including NTCD-M3, a Phase 3 all set treatment for the prevention of C. difficile an infection (CDI) recurrence which is the major trigger of clinic obtained infections in the US. Destiny’s pipeline also incorporates XF-73 nasal gel, which has just lately done a good Stage 2b medical demo focusing on the avoidance of write-up-surgical staphylococcal medical center bacterial infections together with MRSA. The enterprise is also co-building SPOR-COV, a novel, biotherapeutic solution for the prevention of COVID-19 and other viral respiratory bacterial infections.